Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, Paul Audhya, George L Bakris, Melanie Chin, Melissa Krauth, Hiddo J Lambers Heerspink, Colin J Meyer, John J McMurray, Hans-Henrik Parving, Pablo E Pergola, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, David G Warnock, Janet Wittes, Glenn M Chertow

    86 Citationer (Scopus)

    Abstract

    Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
    OriginalsprogEngelsk
    TidsskriftAmerican Journal of Nephrology
    Vol/bind37
    Udgave nummer3
    Sider (fra-til)212-22
    Antal sider11
    ISSN0250-8095
    DOI
    StatusUdgivet - 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)'. Sammen danner de et unikt fingeraftryk.

    Citationsformater